Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Moving toward disease modification in polycythemia vera

Jan Philipp Bewersdorf, Joan How, Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, John Mascarenhas, Raajit K. Rampal

Blood (2023) 142 (22): 1859–1870.

https://doi.org/10.1182/blood.2023021503

Published: 2023

Journal Articles

Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) with Missing Molecular Data

Blood (2023) 142 (Supplement 1): 4607.

https://doi.org/10.1182/blood-2023-187053

Published: 2023

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Journal Articles

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)

Cristina Astrid Tentori, Caterina Gregorio, Marie Robin, Nico Gagelmann, Carmelo Gurnari, Somedeb Ball, Juan Carlos Caballero Berrocal, Luca Lanino, Saverio D'Amico, Marta Spreafico, Giulia Maggioni, Erica Travaglino, Elisabetta Sauta, Manja Meggendorfer, Lin-Pierre Zhao, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Maria Borin, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Jan Philipp Bewersdorf, Olivier Nibourel, Marina Díaz-Beyá, Andres Jerez, Francisca Maria Hernandez, Kyra Velázquez Kennedy, Blanca Xicoy, Marta Ubezio, Alessia Campagna, Antonio Russo, Gabriele Todisco, Daniele Mannina, Stefania Bramanti, Matteo Zampini, Elena Riva, Marilena Bicchieri, Gianluca Asti, Filippo Viviani, Alessandro Buizza, Benedetta Tinterri, Andrea Bacigalupo, Alessandro Rambaldi, Francesco Passamonti, Fabio Ciceri, Victor Savevski, Armando Santoro, Najla H Al Ali, David A Sallman, Francesc Sole, Guillermo Garcia-Manero, Ulrich Germing, Shahram Kordasti, Valeria Santini, Guillermo Sanz, Wolfgang Kern, Anne Sophie Kubasch, Uwe Platzbecker, Maria Diez-Campelo, Jaroslaw P. Maciejewski, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Amer M. Zeidan, Gastone Castellani, Rami S. Komrokji, Francesca Ieva, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 197.

https://doi.org/10.1182/blood-2023-182194

Published: 2023

Journal Articles

Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United States

Jessica M. Stempel, Allison J. Li, Alexander B Pine, Valentina Restrepo, Jan Philipp Bewersdorf, Maximilian Stahl, Nikolai A. Podoltsev, Lourdes Mendez, Rory M. Shallis, Deepa Rangachari, Alfred I Lee, Laura C. Michaelis, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 2319.

https://doi.org/10.1182/blood-2023-187163

Published: 2023

Journal Articles

Validation of the Composite Complete Response (cCR) Definitions in the International Working Group (IWG) 2023 Criteria in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Treated with Hypomethylating Agents (HMA) - a Large, Multicenter, Retrospective Analysis from the Validate Database

Blood (2023) 142 (Supplement 1): 324.

https://doi.org/10.1182/blood-2023-180299

Published: 2023

Journal Articles

Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 Trial

Rory M. Shallis, Ondrej Blaha, Stephanie Halene, Lourdes Mendez, Nikolai A. Podoltsev, Anne Caldwell, Jan Philipp Bewersdorf, Richard F. Little, Richard Piekarz, Mrinal M. Patnaik, Steven D. Gore, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2023-182814

Published: 2023

Journal Articles

Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis

Helen Ajufo, Jan Philipp Bewersdorf, Claire N Harrison, Francesca Palandri, John Mascarenhas, Jeanne Palmer, Aaron T. Gerds, Jean-Jacques Kiladjian, Sarah Buckley, Andriy Derkach, Karisse Roman-Torres, Raajit K. Rampal

Blood (2023) 142 (Supplement 1): 3207.

https://doi.org/10.1182/blood-2023-177643

Published: 2023

Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT)

Blood (2023) 142 (Supplement 1): 4980.

https://doi.org/10.1182/blood-2023-186578

Published: 2023

Journal Articles

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Shai Shimony, Jan Philipp Bewersdorf, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, Evan C. Chen, Jorge Ramos, R. Coleman Lindsley, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl

Blood (2023) 142 (Supplement 1): 1478.

https://doi.org/10.1182/blood-2023-172763

Published: 2023

Journal Articles

Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

Blood (2023) 142 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2023-178728

Published: 2023

Journal Articles

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, R. Coleman Lindsley, Evan C. Chen, Jorge Ramos, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl

Blood (2023) 142 (Supplement 1): 2964.

https://doi.org/10.1182/blood-2023-174285

Published: 2023

Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)

Blood (2023) 142 (Supplement 1): 3240.

https://doi.org/10.1182/blood-2023-186340

Published: 2023

Journal Articles

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Blood (2023) 142 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2023-185315

Published: 2023

Journal Articles

TP53 Y220C Mutations in Patients with Myeloid Malignancies

Georgina Gener-Ricos, Jan Philipp Bewersdorf, Sanam Loghavi, Aaron D. Goldberg, Christopher Famulare, Ghayas C. Issa, Gautam Borthakur, Tapan M. Kadia, Bing Z. Carter, Keyur P. Patel, Michael Andreeff, Eytan M. Stein, Courtney D. DiNardo

Blood (2023) 142 (Supplement 1): 1477.

https://doi.org/10.1182/blood-2023-189343

Published: 2023

Journal Articles

Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database

Blood (2023) 142 (Supplement 1): 1002.

https://doi.org/10.1182/blood-2023-186875

Published: 2023

Journal Articles

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Blood (2023) 142 (Supplement 1): 1589.

https://doi.org/10.1182/blood-2023-174283

Published: 2023

Journal Articles

Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy

Talha Badar, Ehab L. Atallah, Rory M. Shallis, Anand Ashwin Patel, Guilherme Sacchi De Camargo Correia, Aaron D. Goldberg, Antoine Saliba, Jan Philipp Bewersdorf, Adam S Duvall, Danielle Bradshaw, Yasmin Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Vamsi K. Kota, Mark R. Litzow

Blood (2023) 142 (Supplement 1): 592.

https://doi.org/10.1182/blood-2023-184626

Published: 2023

Journal Articles

E7820, an Anti-Cancer Sulfonamide, in Combination with Venetoclax in Patients with Splicing Factor Mutant Myeloid Malignancies: A Phase II Clinical Trial

Jan Philipp Bewersdorf, Namrata Sonia Chandhok, Justin M. Watts, Andriy Derkach, Omar Abdel-Wahab, Eytan M. Stein, Justin Taylor

Blood (2023) 142 (Supplement 1): 1547.

https://doi.org/10.1182/blood-2023-182369

Published: 2023

NARROW

Risk prediction for clonal cytopenia: multicenter real-world evidence

Moving toward disease modification in polycythemia vera

Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) with Missing Molecular Data

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)

Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United States

Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 Trial

Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT)

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

TP53 Y220C Mutations in Patients with Myeloid Malignancies

Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy

E7820, an Anti-Cancer Sulfonamide, in Combination with Venetoclax in Patients with Splicing Factor Mutant Myeloid Malignancies: A Phase II Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only